
OPKO Health OPK
$ 1.22
-1.61%
Quarterly report 2025-Q2
added 07-31-2025
OPKO Health Accounts Payables 2011-2026 | OPK
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47.1 M | 69.7 M | 67 M | 82 M | 101 M | 62.5 M | 47.4 M | 74.3 M | 53.4 M | 72.5 M | 8.74 M | 13.4 M | 10.2 M | 4.89 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 101 M | 4.89 M | 51 M |
Quarterly Accounts Payables OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56.7 M | 59.4 M | 62.7 M | 82.2 M | 71.2 M | 66.8 M | 87.9 M | 80.5 M | 67 M | 49.7 M | - | 94.2 M | 82 M | 94.4 M | 88.5 M | 163 M | 101 M | 101 M | 101 M | 101 M | 62.5 M | 62.5 M | 62.5 M | 62.5 M | 47.4 M | 47.4 M | 47.4 M | 47.4 M | 74.3 M | 74.3 M | 74.3 M | 74.3 M | 53.4 M | 53.4 M | 53.4 M | 53.4 M | 72.5 M | 72.5 M | 72.5 M | 72.5 M | 8.74 M | 8.74 M | 8.74 M | 8.74 M | 13.4 M | 13.4 M | 13.4 M | 13.4 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 4.89 M | 4.89 M | 4.89 M | 4.89 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 163 M | 4.89 M | 54.5 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
446 M | $ 120.96 | -0.75 % | $ 36.8 B | ||
|
Burning Rock Biotech Limited
BNR
|
63.1 M | $ 21.56 | 4.31 % | $ 232 M | ||
|
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | ||
|
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | ||
|
Check-Cap Ltd.
CHEK
|
952 K | - | - | $ 9.42 M | ||
|
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | ||
|
Danaher Corporation
DHR
|
1.84 B | $ 195.5 | 0.39 % | $ 139 B | ||
|
CareDx, Inc
CDNA
|
9.99 M | $ 21.29 | -0.61 % | $ 1.13 B | ||
|
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | ||
|
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | ||
|
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
1.88 M | $ 1.67 | 7.05 % | $ 2.22 M | ||
|
Exact Sciences Corporation
EXAS
|
176 M | - | - | $ 19.8 B | ||
|
Castle Biosciences
CSTL
|
6.9 M | $ 25.16 | 0.44 % | $ 699 M | ||
|
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | ||
|
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | ||
|
Charles River Laboratories International
CRL
|
149 M | $ 185.54 | 0.9 % | $ 9.2 B | ||
|
Interpace Biosciences
IDXG
|
983 K | $ 2.05 | -4.17 % | $ 9.07 M | ||
|
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | ||
|
Illumina
ILMN
|
221 M | $ 132.86 | -1.22 % | $ 21.1 B | ||
|
Fulgent Genetics
FLGT
|
18.4 M | $ 16.18 | -0.49 % | $ 489 M | ||
|
Medpace Holdings
MEDP
|
28.1 M | $ 528.44 | 1.51 % | $ 15.2 B | ||
|
Guardant Health
GH
|
54.4 M | $ 91.07 | 0.79 % | $ 11.4 B | ||
|
QIAGEN N.V.
QGEN
|
72.7 M | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
295 K | $ 2.18 | - | $ 5.01 M | ||
|
Senseonics Holdings
SENS
|
4.06 M | $ 6.87 | 1.48 % | $ 287 M | ||
|
ICON Public Limited Company
ICLR
|
173 M | $ 117.12 | -2.14 % | $ 9.66 B | ||
|
Laboratory Corporation of America Holdings
LH
|
841 M | $ 269.19 | -0.55 % | $ 22.4 B | ||
|
Celcuity
CELC
|
6.41 M | $ 120.09 | -1.94 % | $ 5.62 B | ||
|
Lantheus Holdings
LNTH
|
42.9 M | $ 83.97 | 0.18 % | $ 5.67 B | ||
|
ENDRA Life Sciences
NDRA
|
383 K | $ 6.01 | -6.03 % | $ 4.73 M | ||
|
NeoGenomics
NEO
|
23.1 M | $ 8.23 | -1.44 % | $ 1.05 B | ||
|
Myriad Genetics
MYGN
|
30 M | $ 5.14 | 1.18 % | $ 476 M | ||
|
Quest Diagnostics Incorporated
DGX
|
307 M | $ 196.31 | 0.66 % | $ 21.8 B | ||
|
Natera
NTRA
|
31.1 M | $ 207.74 | -0.32 % | $ 20.4 B | ||
|
Neogen Corporation
NEOG
|
79.6 M | $ 9.63 | 1.26 % | $ 2.09 B | ||
|
Invitae Corporation
NVTA
|
14 M | - | - | $ 21.2 M | ||
|
National Research Corporation
NRC
|
1.17 M | $ 18.18 | 0.83 % | $ 407 M | ||
|
Organovo Holdings
ONVO
|
1.64 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
245 K | - | -16.95 % | $ 1.54 M | ||
|
Pacific Biosciences of California
PACB
|
20.8 M | $ 1.74 | 2.96 % | $ 522 M |